BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//PlainTrial//Saved Trials Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PlainTrial saved trials
X-WR-CALDESC:Estimated completion dates for the clinical trials you saved o
 n PlainTrial.
BEGIN:VEVENT
UID:plaintrial-NCT03821935-completion@plaintrial.com
DTSTAMP:20261028T005130Z
DTSTART;VALUE=DATE:202706
SUMMARY:Study to Determine the Safety\, Tolerability\, Pharmacokinetics and
  Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single A
 gent and in Combination With Budigalimab (ABBV-181) in Participants With L
 ocally Advanced or Metastatic Solid Tumors — estimated completion date
DESCRIPTION:Active\, not recruiting. Saved on your PlainTrial shortlist. Fu
 ll trial record: https://plaintrial.com/trial/NCT03821935
URL:https://plaintrial.com/trial/NCT03821935
END:VEVENT
END:VCALENDAR